Report || Other EAS 2020 news

Bempedoic acid in heterozygous FH

This study pooled data from two phase 3 placebo-controlled trials of bempedoic acid (180 mg) in 3009 patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolaemia (FH) on maximally tolerated statin therapy with or without other nonstatin therapy. The duration of treatment was 52 weeks, and the primary efficacy endpoint was percent change from baseline to week 12 in LDL cholesterol.

Mean LDL cholesterol reductions from baseline to week 12 were significantly greater with bempedoic acid versus placebo for patients with heterozygous FH (placebo-corrected, 22.3%) and without (18.3%), p<0.001 for both analyses.  These findings suggest that bempedoic acid, on top of statin, may be another therapeutic option in this patient group.

Duell PB et al. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials 

Presented in session Sterols at the crossroad of metabolic pathways available to view on demand

CETP inhibition and macular degeneration

Cholesteryl ester transfer protein (CETP) facilitates the exchange of triglycerides for cholesteryl esters between non-HDL and HDL particles. Despite resulting in a favourable lipid profile characterised by low non-HDL cholesterol levels, randomized controlled trials have failed to show definitive clinical benefit. Side effects such as age-related macular degeneration and dementia have also been suggested, providing a rationale for further study. A weighted allele score based on eight common CETP variants was constructed using two Danish general population studies in over 100,000 people to investigate the association with risk of vascular dementia, Alzheimer’s dementia, age-related macular degeneration, cardiovascular mortality and ischemic heart disease.

Genetic inhibition of CETP, mimicking treatment with CETP inhibitors, was associated with lower risk of vascular dementia, cardiovascular mortality and ischemic heart disease, but a 28% higher risk of age-related macular degeneration, suggesting that this may be a long-term side-effect of pharmacological CETP inhibition.

Nordestgaard LT. Genetic inhibition of CETP and risk of dementia, age-related macular degeneration and cardiovascular mortality.

Presented in session Lipoprotein receptors and lipid transport

Copenhagen Baby Heart: Umbilical cord blood a proxy for neonatal blood

The coagulation system is not fully developed at birth and reference ranges are uncertain, complicating clinical decision making. Data from the Copenhagen Baby Heart cohort of 25,745 subjects showed that umbilical cord blood was a good proxy for neonatal blood for haemostatic parameters.

Nielsen, ST. Thrombosis and haemostasis parameters in early life: Copenhagen Baby Heart and COMPARE studies.

Presented in session Rapid fire Session #4 – Clinical Lipidology and Cardiovascular Disease available to view on demand